We are live on ! Find out more
KM

Kalos Management Portfolio holdings

AUM $46.6M
1-Year Est. Return 11.52%
This Fund
S&P 500
This Quarter Est. Return
+1.69%
1 Year Est. Return
+11.52%
3 Year Est. Return
+48.48%
5 Year Est. Return
+71.6%
10 Year Est. Return
–
AUM
$251M
AUM Growth
+$30.8M
Cap. Flow
+$17.5M
Cap. Flow %
6.98%
Top 10 Hldgs %
27.72%
Holding
245
New
51
Increased
59
Reduced
72
Closed
46

Top Buys

Rank Stock Value
1
CMI icon
Cummins
CMI
+$2.96M
2
ADEA icon
Adeia
ADEA
+$2.77M
3
CXSE icon
WisdomTree Trust WisdomTree China ex-State-Owned Enterprises Fund
CXSE
+$2.74M
4
TAP icon
Molson Coors Class B
TAP
+$2.32M
5
PFG icon
Principal Financial Group
PFG
+$2.26M

Top Sells

Rank Stock Value
1
IVE icon
iShares S&P 500 Value ETF
IVE
+$5.63M
2
VOO icon
Vanguard S&P 500 ETF
VOO
+$3.85M
3
LRCX icon
Lam Research
LRCX
+$2.82M
4
JPM icon
JPMorgan Chase
JPM
+$2.41M
5
TD icon
Toronto Dominion Bank
TD
+$2.18M

Sector Composition

Rank Sector Weight
1 Technology 9.97%
2 Healthcare 7.77%
3 Financials 6.18%
4 Consumer Discretionary 4.09%
5 Industrials 3.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XT icon
176
iShares Future Exponential Technologies ETF
XT
$3.82B
$201K 0.08%
+5,208
New +$201K
VKQ icon
177
Invesco Municipal Trust
VKQ
$541M
$186K 0.07%
14,750
– –
MAV
178
DELISTED
Pioneer Municipal High Income Advantage Fund
MAV
$180K 0.07%
16,400
– –
AUY
179
DELISTED
Yamana Gold, Inc.
AUY
$150K 0.06%
47,343
+36,719
+346% +$117K
ENBL
180
DELISTED
ENABLE MIDSTREAM PARTNERS, LP
ENBL
$142K 0.06%
+11,858
New +$155K
PRTK
181
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$107K 0.04%
25,050
-5,000
-17% -$20K
UDF
182
DELISTED
UNITED DEV FDG IV COM SHS OF BENE INT (TX)
UDF
$101K 0.04%
33,364
-3,437
-9% -$10.4K
GYRE icon
183
Gyre Therapeutics
GYRE
$641M
$90K 0.04%
2,441
+133
+6% +$7.17K
FOLD
184
DELISTED
Amicus Therapeutics
FOLD
$87K 0.03%
10,850
– –
EXK
185
Endeavour Silver
EXK
$2.23B
$85K 0.03%
+38,251
New +$92.5K
PSLV icon
186
Sprott Physical Silver Trust
PSLV
$12B
$77K 0.03%
12,367
– –
CTSO icon
187
Cytosorbents Corp
CTSO
$22.7M
$67K 0.03%
13,500
– –
BCRX icon
188
BioCryst Pharmaceuticals
BCRX
$2.28B
$53K 0.02%
+18,950
New +$58.9K
SACH
189
Sachem Capital Corp
SACH
$39.1M
$51K 0.02%
11,000
– –
HTGM
190
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$46K 0.02%
372
– –
NGNE icon
191
Neurogene
NGNE
$656M
$42K 0.02%
745
– –
PFX icon
192
PhenixFIN
PFX
$33K 0.01%
675
– –
AGRX
193
DELISTED
Agile Therapeutics
AGRX
$21K 0.01%
+9
New +$22.2K
VSTM icon
194
Verastem
VSTM
$510M
$14K 0.01%
1,083
-1,355
-56% -$22K
HSTO
195
DELISTED
Histogen Inc. Common Stock
HSTO
$14K 0.01%
238
– –
MTVA
196
MetaVia Inc
MTVA
$7.33M
– –
0
– –
EFOR
197
Everforth Inc
EFOR
$1.17B
– –
-8,855
Closed -$482K
ATKR icon
198
Atkore
ATKR
$2.46B
– –
-44,670
Closed -$886K
BAC icon
199
Bank of America
BAC
$435B
– –
-7,495
Closed -$217K
CMRE icon
200
Costamare
CMRE
$1.88B
– –
-425,266
Closed -$1.87M
6 7
8
9 10

Similar funds

IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return
UCIG
Ulrich Consultants & Investment Group Albuquerque, New Mexico $41.4M AUM 20.81% 1-Year Est. Return
KP
Kuvari Partners London, United Kingdom $52.2M AUM
NH
NNS Holding Camana Bay, Grand Cayman, Cayman Islands $53.2M AUM
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
VCM
Voce Capital Management San Francisco, California $57.8M AUM 9.28% 1-Year Est. Return
FGIM
First Growth Investment Manager San Francisco, California $59.5M AUM 30.53% 1-Year Est. Return
WGRM
Waterton Global Resource Management Toronto, Ontario, Canada $64.9M AUM 17.81% 1-Year Est. Return

Kalos Management's Q3 2019 Portfolio in Review

As of Q3 2019, Kalos Management held 245 positions worth $251M, up 14% from $220M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Kalos Management deployed $17.5M of net new capital in Q3 2019, opening 51 new positions and adding to 59 existing holdings. Its largest new stake was Cummins: 18,500 shares worth $3.01M.

By sector, the portfolio is most concentrated in Technology at 10% of assets, down from 10% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was iShares S&P 500 Value ETF, an estimated $5.63M trimmed.

  • Kalos Management's largest Q3 2019 buy was Cummins: 18,500 shares worth $3.01M.
  • Kalos Management added most to State Street SPDR S&P 500 ETF Trust in Q3 2019, an estimated $1.8M increase.
  • Kalos Management's biggest Q3 2019 reduction was iShares S&P 500 Value ETF, cutting an estimated $5.63M.
  • Kalos Management fully exited Vanguard S&P 500 ETF in Q3 2019, selling an estimated $3.85M.
  • Kalos Management's ten largest holdings make up 28% of its $251M portfolio in Q3 2019.
  • Kalos Management opened 51 new positions and closed 46 in Q3 2019.
  • Kalos Management's portfolio value rose 14% quarter-over-quarter to $251M.

Based on Kalos Management's 13F filing for Q3 2019, filed 14 Nov 2019.